Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

DIPSS (Myelofibrosis)

The DIPSS estimates survival in patients with Primary Myelofibrosis.

Evidence-based context for fast calculator use

Purpose:
DIPSS estimates survival in Primary Myelofibrosis at any disease timepoint using age, blood counts, blasts, and symptoms to guide transplant decisions.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age > 65 years?, Constitutional Symptoms?, Hemoglobin < 10 g/dL?, WBC > 25 x 10⁹/L?, Circulating Blasts ≥ 1%?
Reference:
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
HomeDIPSS (Myelofibrosis)
Pin your most used calculators here by clicking the star in the dropdown.

DIPSS (Myelofibrosis)

Clinical Context & Background

The DIPSS estimates survival in patients with Primary Myelofibrosis. Unlike the IPSS (used at diagnosis), DIPSS can be used at any time during the disease course. It evaluates Age, White Blood Cell count, Hemoglobin, Peripheral Blasts, and Constitutional Symptoms.
Primary Source EvidencePassamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
Formula Logic
Sum of points (0-6). Hb < 10 gets 2 points, others 1 point.

Reference Data

Risk GroupScoreMedian Survival
Low0Not Reached (15+ years)
Intermediate-11 - 214.2 years
Intermediate-23 - 44 years
High5 - 61.5 years

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use DIPSS (Myelofibrosis) when dIPSS estimates survival in Primary Myelofibrosis at any disease timepoint using age, blood counts, blasts, and symptoms to guide transplant decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age > 65 years?, Constitutional Symptoms?, Hemoglobin < 10 g/dL?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should DIPSS (Myelofibrosis) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can DIPSS (Myelofibrosis) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.